Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Eight-Week Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (300/5 mg and 300/10 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy.

Next Previous
Search
Trial Profile

A Randomized, Eight-Week Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (300/5 mg and 300/10 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren/amlodipine (Primary) ; Aliskiren
  • Indications Essential hypertension
  • Focus Biomarker; Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 24 Jan 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 30 Jun 2011 Additional locations identified as reported by ClinicalTrials.gov record.
    • 25 Dec 2010 Additional lead trial investigator identified as reported by Clinical Trials Registry - India record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top